Literature DB >> 25023206

Psychiatric morbidity in ketamine users attending counselling and youth outreach services.

Wai Kwong Tang1, Celia J A Morgan, Grace C Lau, Hua Jun Liang, Alan Tang, Gabor S Ungvari.   

Abstract

BACKGROUND: No study has examined ketamine users' psychiatric morbidity using structured diagnostic instruments. The aim of this study was thus to determine the psychiatric comorbidity of community-based ketamine users using the Structured Clinical Interview for DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition), Axis I Disorders (SCID).
METHODS: A convenience sample of 200 frequent ketamine users was recruited from community organizations in Hong Kong. Participants were screened with the Severity of Dependence Scale (SDS), Beck Depression Inventory (BDI), Anxiety subscale of the Hospital Anxiety Depression Scale (HADSA), and SCID psychotic symptoms. Those who scored above the threshold (cutoff point of 8/9 on the BDI and 4/5 on HADSA) or displayed evidence of psychotic symptoms were referred for a structured clinical interview conducted by a psychiatrist.
RESULTS: One hundred and seventy participants scored above the cutoff point on 1 or more of the scales, and 115 participants attended the SCID interview. Fifty-one of these 115 participants received a psychiatric diagnosis of 1 or more comorbidities for the month preceding the interview. Mood disorders accounted for 80.4% of the diagnoses, anxiety disorders for 33.3%, and psychotic disorders for 7.8%.
CONCLUSIONS: Female gender and history of psychiatric/psychological clinic attendance were significantly associated with comorbid psychiatric disorders, whereas ketamine dependence had a borderline association.

Entities:  

Keywords:  Depression; ketamine; psychiatric comorbidity; psychotic disorders; substance use disorder

Mesh:

Substances:

Year:  2014        PMID: 25023206     DOI: 10.1080/08897077.2014.935560

Source DB:  PubMed          Journal:  Subst Abus        ISSN: 0889-7077            Impact factor:   3.716


  4 in total

1.  Test-retest reliability and cross-cultural applicability of DSM-5 adopted diagnostic criteria for ketamine use disorders.

Authors:  Nicole D Fitzgerald; Catherine W Striley; Joseph J Palamar; Jan Copeland; Steven Kurtz; Linda B Cottler
Journal:  Drug Alcohol Depend       Date:  2021-09-21       Impact factor: 4.492

2.  Sex differences in response to ketamine as a rapidly acting intervention for treatment resistant depression.

Authors:  Marlene P Freeman; George I Papakostas; Bettina Hoeppner; Erica Mazzone; Heidi Judge; Cristina Cusin; Sanjay Mathew; Gerard Sanacora; Dan Iosifescu; Charles DeBattista; Madhukar H Trivedi; Maurizio Fava
Journal:  J Psychiatr Res       Date:  2019-01-08       Impact factor: 4.791

3.  Profiling the psychotic, depressive and anxiety symptoms in chronic ketamine users.

Authors:  Ni Fan; Ke Xu; Yuping Ning; Robert Rosenheck; Daping Wang; Xiaoyin Ke; Yi Ding; Bin Sun; Chao Zhou; Xuefeng Deng; Waikwong Tang; Hongbo He
Journal:  Psychiatry Res       Date:  2016-01-14       Impact factor: 3.222

4.  Decreased Thalamocortical Connectivity in Chronic Ketamine Users.

Authors:  Yanhui Liao; Jinsong Tang; Jianbin Liu; An Xie; Mei Yang; Maritza Johnson; Xuyi Wang; Qijian Deng; Hongxian Chen; Xiaojun Xiang; Tieqiao Liu; Xiaogang Chen; Ming Song; Wei Hao
Journal:  PLoS One       Date:  2016-12-15       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.